Mission: The addario lung cancer medical institute (alcmi) is dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients.
Programs: The addario lung cancer medical institute (alcmi) is dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients. Alcmi is a patient-founded, patient-focused research consortium. Its goal is to make lung cancer a chronically managed disease. Alcmi was created in 2008, as a partner organization with the bonnie j addarios lung cancer foundation (alcf), to enable the collection and analysis of tissue and blood samples which are essential to research and to the development of individually tailored (and more effective) therapies. Alcmi is unique. It is a comprehensively contracted consortium with shared infrastructures (standardized contracts, data systems and biorepositories) and centrally coordinated scientific planning. Alcmi's researchers are pooling their knowledge, specimens and data in order to improve the understanding of the molecular bases of lung cancer and to accelerate the development and delivery of much more effective, targeted drugs and treatments tailored to individual patients. Alcmi has developed and launched three innovative research studies that would otherwise not have exisited: 1) castle prospective, longitudinal, multi-center study with biobank, annotated with clinical/molecular data and matched, serial biospecimens from advanced stage lung cancer; 2) inherit egfr t790m: prospective study on germline biology in high-risk families, to identify specific inherited genetic markers indicating riks of developing lung cancer; and 3) genomics of young lung cancer: prospectively perform comprehensive genomic profiling to determine whether young lung cancers harbor a distinctive spectrum of genetic mutations, and therefore unique treatment strategies.